LumiraDx Teams Up with AstraZeneca & Everton in the Community to Open England’s First Heart & Lung Screening Hub

DENVER, Colo., Oct 23, 2023 ( LumiraDx Limited (NASDAQ:LMDX) announced, after Friday’s market close, that it formed a strategic collaboration with AstraZeneca and Everton in the Community to set up England’s first community-based heart and lung screening hub, which is scheduled for November opening.

The collaboration is the result of an unrestricted grant funding from AstraZeneca and run by Everton in the Community, the official charity of Everton Football Club. The Liverpool-based hub will provide significant support for individuals suffering from chronic breathlessness and other heart and lung-related conditions in a community-based setting.

LumiraDx is trading at $0.279, up $0.19 (+212.56%), on 27.29M premarket shares traded.

Its 52-week range is $ 0.0849 to 1.61. This move is a massive bounce from the 52-week low that it hit Friday and 32-cents is its next key inflection point.

 24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.